View More Recent Stories

Dec 16, 2024 07:37AM Trevi Therapeutics (TRVI) Prices 12.5M Share Offering at $4/sh
Dec 12, 2024 07:30AM Trevi Therapeutics (TRVI) Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Pati
Dec 4, 2024 06:09AM Oppenheimer Reiterates Outperform Rating on Trevi Therapeutics (TRVI)
Dec 3, 2024 04:06PM Trevi Therapeutics (TRVI) Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
Nov 6, 2024 04:34PM Trevi Therapeutics (TRVI) Misses Q3 EPS by 1c
Oct 22, 2024 06:59AM H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI)
Oct 8, 2024 05:47AM Oppenheimer Reiterates Outperform Rating on Trevi Therapeutics (TRVI)
Oct 4, 2024 12:48PM B.Riley Reiterates Buy Rating on Trevi Therapeutics (TRVI)
Oct 4, 2024 07:48AM EF Hutton Reiterates Buy Rating on Trevi Therapeutics (TRVI)
Oct 3, 2024 04:11PM Trevi Therapeutics (TRVI) Provides Update on Haduvio's Clinical Development Program
Sep 30, 2024 05:42PM Trevi Therapeutics (TRVI) Appoints James V. Cassella as Chief Development Officer
Sep 9, 2024 12:10PM Leerink Partners Assumes Trevi Therapeutics (TRVI) at Outperform 'based on the potential of lead asset Haduvio'
Aug 30, 2024 06:41AM Raymond James Starts Trevi Therapeutics (TRVI) at Outperform
Aug 30, 2024 06:23AM H.C. Wainwright Starts Trevi Therapeutics (TRVI) at Buy
Aug 19, 2024 07:01AM EF Hutton Starts Trevi Therapeutics (TRVI) at Buy
Aug 8, 2024 04:20PM Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c
View More Recent Stories